Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AMRX

AMRX - Amneal Pharmaceuticals Inc Stock Price, Fair Value and News

$13.95+0.12 (+0.87%)
Market Closed

18/100

AMRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

18/100

AMRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$10.71

Target 3M

$12.05

Target 6M

$11.38

AMRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AMRX Price Action

Last 7 days

1.8%

Last 30 days

8.1%

Last 90 days

39.5%

Trailing 12 Months

59.8%

AMRX RSI Chart

AMRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AMRX Valuation

Market Cap

4.4B

Price/Earnings (Trailing)

89.66

Price/Sales (Trailing)

1.49

EV/EBITDA

23.63

Price/Free Cashflow

16.59

AMRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$10.71

Target 3M

$12.05

Target 6M

$11.38

AMRX Fundamentals

AMRX Revenue

Revenue (TTM)

2.9B

Rev. Growth (Yr)

11.68%

Rev. Growth (Qtr)

8.28%

AMRX Earnings

Earnings (TTM)

48.9M

Earnings Growth (Yr)

1.6K%

Earnings Growth (Qtr)

-89.43%

AMRX Profitability

EBT Margin

2.34%

Return on Equity

-44.48%

Return on Assets

1.36%

Free Cashflow Yield

6.03%

AMRX Investor Care

Shares Dilution (1Y)

1.46%

Diluted EPS (TTM)

0.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.8B2.9B2.9B0
20242.5B2.6B2.7B2.8B
20232.3B2.3B2.4B2.4B
20222.1B2.1B2.1B2.2B
20212.0B2.1B2.1B2.1B
20201.7B1.7B1.9B2.0B
20191.8B1.8B1.7B1.6B
20181.1B1.2B1.5B1.7B
20171.0B1.0B1.0B1.0B
20160001.0B
Get all data in R, Python etc through our Historical Stock Data APIs

About Amneal Pharmaceuticals Inc

AMRX
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
 CEO
 WEBSITEhttps://amneal.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES7600

Amneal Pharmaceuticals Inc Frequently Asked Questions

AMRX is the stock ticker symbol of Amneal Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Amneal Pharmaceuticals Inc is 4.39 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AMRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether AMRX is over valued or under valued. Whether Amneal Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Amneal Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMRX.

As of Wed Jan 28 2026, AMRX's PE ratio (Price to Earnings) is 89.66 and Price to Sales (PS) ratio is 1.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMRX PE ratio will change depending on the future growth rate expectations of investors.